

**Member Name:** \_\_\_\_\_ **Date of Birth:** \_\_\_\_\_ **Member ID#:** \_\_\_\_\_**Drug Information**☐ **Physician billing (HCPCS code:** \_\_\_\_\_ **)** ☐ **Pharmacy billing (NDC:** \_\_\_\_\_ **)****Dose:** \_\_\_\_\_ **Regimen:** \_\_\_\_\_ **Start Date:** \_\_\_\_\_**Billing Provider Information****Provider NPI:** \_\_\_\_\_ **Provider Name:** \_\_\_\_\_**Provider Phone:** \_\_\_\_\_ **Provider Fax:** \_\_\_\_\_**Prescriber Information****Prescriber NPI:** \_\_\_\_\_ **Prescriber Name:** \_\_\_\_\_**Prescriber Phone:** \_\_\_\_\_ **Prescriber Fax:** \_\_\_\_\_ **Specialty:** \_\_\_\_\_**Criteria****For Initial Authorization (Initial approval will be for the duration of 6 months):**

1. Please indicate member's diagnosis:

☐ **Heterozygous familial hypercholesterolemia (HeFH)** confirmed by 1 or more of the following:

- ☐ Documented functional mutation(s) in low-density lipoprotein (LDL) receptor alleles or alleles known to affect LDL receptor functionality via genetic testing (*results of genetic testing must be submitted*)
- ☐ Pre-treatment total cholesterol >290mg/dL or LDL-cholesterol (LDL-C) >190mg/dL
- ☐ History of tendon xanthomas in either the member, first degree relative, or second degree relative
- ☐ Dutch Lipid Clinic Network Criteria score of >8

☐ **Established atherosclerotic cardiovascular disease (ASCVD).** Please provide supporting diagnoses/conditions and dates of occurrence signifying established ASCVD:

Diagnosis/condition: \_\_\_\_\_ Date of occurrence: \_\_\_\_\_

Diagnosis/condition: \_\_\_\_\_ Date of occurrence: \_\_\_\_\_

☐ **Primary hyperlipidemia**

- ☐ Untreated LDL-C level  $\geq 190$ mg/dL
- ☐ Current LDL-C level  $\geq 100$ mg/dL

2. Will Leqvio® be used as an adjunct to diet and statin therapy? Yes \_\_\_\_\_ No \_\_\_\_\_

3. Has member tried any of the following medications? Check all that apply. Provide trial dates and specific medication if applicable.

a. \_\_\_\_\_ Statin therapy; dates: \_\_\_\_\_

i. Medication/strength: \_\_\_\_\_ Dosing regimen: \_\_\_\_\_

b. \_\_\_\_\_ Ezetimibe; dates: \_\_\_\_\_

c. \_\_\_\_\_ Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor; dates: \_\_\_\_\_

ii. Medication/strength: \_\_\_\_\_ Dosing regimen: \_\_\_\_\_

**(Page 1 of 2)**

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at [AetnaBetterHealth.com/Oklahoma](http://AetnaBetterHealth.com/Oklahoma).

**CONFIDENTIALITY NOTICE**

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*

**Member Name:** \_\_\_\_\_ **Date of Birth:** \_\_\_\_\_ **Member ID#:** \_\_\_\_\_**Criteria****For Initial Authorization: (continued)**

4. If the member has **not** been on a stable dose of statin therapy for at least 4 weeks, is the member intolerant to statin therapy? Yes \_\_\_\_\_ No \_\_\_\_\_
- a. If yes, please indicate 1 of the following:
- ☐ Rhabdomyolysis - creatine kinase (CK) labs verifying this diagnosis must be provided.
  - ☐ An FDA labeled contraindication to all statins. Provide contraindication: \_\_\_\_\_
  - ☐ Documented intolerance to at least 2 different statins at lower doses or at intermittent dosing:  
Please provide all of the following:  
1) Medication/strength: \_\_\_\_\_ Dosing regimen: \_\_\_\_\_  
Duration of treatment: \_\_\_\_\_ Reason for discontinuation: \_\_\_\_\_  
2) Medication/strength: \_\_\_\_\_ Dosing regimen: \_\_\_\_\_  
Duration of treatment: \_\_\_\_\_ Reason for discontinuation: \_\_\_\_\_
5. Member's baseline LDL-C: \_\_\_\_\_ Current LDL-C: \_\_\_\_\_ Goal LDL-C: \_\_\_\_\_
6. Will Leqvio® be administered by a health care professional? Yes \_\_\_\_\_ No \_\_\_\_\_
7. How will Leqvio® will be administered (e.g., prescriber, pharmacist, home health care provider): \_\_\_\_\_
8. If Leqvio® will be administered in a health care facility, will it be shipped directly to the facility? Yes \_\_\_\_\_ No \_\_\_\_\_
9. If Leqvio® will be dispensed to the member for delivery to a health care provider for administration, has the member been counseled on the proper storage of Leqvio®? Yes \_\_\_\_\_ No \_\_\_\_\_

**For Continued Authorization:**

1. Has member been compliant with Leqvio® treatment? Yes \_\_\_\_\_ No \_\_\_\_\_
2. Please provide a recent LDL-C level for this member: \_\_\_\_\_ Date taken: \_\_\_\_\_

Additional information: \_\_\_\_\_

\_\_\_\_\_

\_\_\_\_\_

**(Page 2 of 2)****Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**By signature, the physician confirms the criteria information above is accurate and verifiable in patient records.**  
Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at [AetnaBetterHealth.com/Oklahoma](https://www.aetna.com/betterhealth/oklahoma).

**CONFIDENTIALITY NOTICE**

*This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.*